The effect of clinically recommended Evolut sizes on anchorage forces after BASILICA.
BASILICA
Finite element analysis
TAVR
Journal
Journal of biomechanics
ISSN: 1873-2380
Titre abrégé: J Biomech
Pays: United States
ID NLM: 0157375
Informations de publication
Date de publication:
30 03 2021
30 03 2021
Historique:
received:
30
12
2020
accepted:
16
01
2021
pubmed:
19
2
2021
medline:
28
5
2021
entrez:
18
2
2021
Statut:
ppublish
Résumé
Coronary artery obstruction (CAO), a fatal complication of transcatheter aortic valve replacement (TAVR), is commonly found after Valve-in-Valve implantation inside a degenerated bioprosthetic valve. Leaflet laceration (BASILICA technique) has been proposed to prevent CAO and to potentially reduce the risk of leaflet thrombosis. We have previously demonstrated that this technique can reduce the anchorage forces of the TAVR device, which may lead to future complications. In this short communication, we hypothesize that the anchorage force reduction can be minimized by implanting a TAVR with a larger diameter, if two sizes are clinically recommended. We evaluated this hypothesis by employing finite element models of the deployments of the Evolut 26 and 29 mm inside a 27 mm Mitroflow valve, with and without leaflet lacerations. The results show that a laceration substantially decreases the contact area between the Evolut stent and the Mitroflow valve. The larger Evolut has a larger contact area and stronger anchorage forces. Additionally, the anchorage forces are less sensitive to additional lacerations in the larger Evolut (29 case). The results suggest that a larger self-expending device can ensure stronger anchorage and can lower the risk of possible migration, when TAVR is performed in a lacerated bioprosthesis.
Identifiants
pubmed: 33601185
pii: S0021-9290(21)00083-X
doi: 10.1016/j.jbiomech.2021.110303
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110303Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Prof. Finkelstein serves as a proctor, advisor and speaker for Medtronic Inc. and for Edwards Lifesciences. The remaining authors have no conflict of interest to declare.